Selective progesterone receptor modulators: current applications and perspectives

References

• Christin-Maitre S, Bouchard P, Spitz IM. Medical termination of pregnancy. N Engl J Med 2000;342:946–56
   PubMed Web of Science ®Google Scholar
• Bouchard P. Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology and gynecology. Gynecol Endocrinol 2014;30:683–4
   PubMed Web of Science ®Google Scholar
• Bouchard P, Chabbert Bufffet N, Fauser BCJM. Selective progesterone modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 2011;96:1175–89
   PubMed Web of Science ®Google Scholar
• Chabbert Buffet N, Pintiaux A, Bouchard P. The immninent dawn of SPRMs in obstetrics and gynecology. Mol Cell Endocrinol 2012;358:232–43
   PubMed Web of Science ®Google Scholar
• Ulmann A. The development of mifepristone: a pharmaceutical drama in three acts. J Am Med Womens Assoc (1972) 2000;55:117–20
   PubMedGoogle Scholar
• Ulmann A, Teutsch G, Philibert D. RU 486. Sci Am 1990;262:42–8
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Skinner DC, Caraty A, Bouchard P. Neuroendocrine effects of progesterone. Steroids 2000;65:613–20
   PubMed Web of Science ®Google Scholar
• Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update 2014;20:485–500
   PubMed Web of Science ®Google Scholar
• Thomas P, Pang Y, Dong J. Enhancement of cell surface expression and receptor functions of membrane progestin receptor α (mPRα) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors. Endocrinology 2014;155:1107–19
   PubMed Web of Science ®Google Scholar
• Singh Susheela WD, Hussain R, Bankole A, Sedgh G. Abortion Worldwide: a Decade of Uneven Progress. New York: Guttmacher Institute; 2009
   Google Scholar
• Jones RK, Darroch JE, Henshaw SK. Contraceptive use among U.S. women having abortions in 2000-2001. Perspect Sex Reprod Health 2002;34:294–303
   PubMed Web of Science ®Google Scholar
• Kaiser Family Foundation. Women’s health care providers experiences with emergency contraception. 2003. Available from: wwwkfforg/womenshealth/3343-indexcfm [last accessed 12 Nov 2010]
   Google Scholar
• Baird DT, Cameron S, Evers JLH, ESHRE Capri Workshop Group and ESHRE Capri Workshop Group, et al. Emergency contraception. Widely available and effective but disappointing as a public health intervention: a review. Hum Reprod 2015;30:751–60
   PubMed Web of Science ®Google Scholar
• Jatlaoui TC, Riley H, Curtis KM. Safety data for levonorgestrel, ulipristal acetate and Yuzpe regimens for emergency contraception. Contraception 2016;93:93–112
   PubMed Web of Science ®Google Scholar
• Baird DT, Thong KJ, Hall C, Cameron ST. Failure of oestrogen induced LH surge in women treated with mifepristone (RU 486) everyday for 30 days. Hum Reprod 1995;10:2270–6
   PubMed Web of Science ®Google Scholar
• Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 2010;375:555–62
   PubMed Web of Science ®Google Scholar
• Brache V, Cochon L, Deniaud M, Croxatto HB. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception 2013;88:611–18
   PubMed Web of Science ®Google Scholar
• Cheng L, Che Y, Gulmezoglu AM. Interventions for emergency contraception. Cochrane Database Syst Rev 2012;8:CD001324
   PubMed Web of Science ®Google Scholar
• Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006;108:1089–97
   PubMed Web of Science ®Google Scholar
• Richardson AR, Maltz FN. Ulipristal acetate: review of the efficacy and safety of a newly approved agent for emergency contraception. Clin Ther 2012;34:24–36
   PubMed Web of Science ®Google Scholar
• Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011;84:363–7
   PubMed Web of Science ®Google Scholar
• Thomin A, Keller V, Daraï E, Chabbert-Buffet N. Consequences of emergency contraceptives: the adverse effects. Expert Opin Drug Saf 2014;13:893–902
   PubMed Web of Science ®Google Scholar
• Fine P, Mathe H, Ginde S, et al. Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. Obstet Gynecol 2010;115:257–63
   PubMed Web of Science ®Google Scholar
• Salcedo J, Rodriguez MI, Curtis KM, Kapp N. When can a woman resume or initiate contraception after taking emergency contraceptive pills? A systematic review. Contraception 2013;87:602–4
   PubMed Web of Science ®Google Scholar
• Cameron ST, Berger C, Michie L, Klipping C, Gemzell-Danielsson K. The effects on ovarian activity of ulipristal acetate when ‘quickstarting’ a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. Hum Reprod 2015;30:1566–72
   PubMed Web of Science ®Google Scholar
• Brache V, Cochon L, Duijkers IJ, et al. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. Hum Reprod 2015;30:2785–93
   PubMed Web of Science ®Google Scholar
• Pohl O, Osterloh I, Gotteland JP. Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate. J Clin Pharm Ther 2013;38:512–17
   PubMed Web of Science ®Google Scholar
• Pohl O, Osterloh I, Lecomte V, Gotteland JP. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther 2013;51:26–33
   PubMed Web of Science ®Google Scholar
• Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med 2015;372:1646–55
   PubMed Web of Science ®Google Scholar
• Chabbert Buffet N, Esber N, Bouchard P. Fibroid growth and medical options for treatment. Fertil Steril 2014;102:630–9
   PubMed Web of Science ®Google Scholar
• Bulun SE. Uterine fibroids. N Engl J Med 2013;369:1344–55
   PubMed Web of Science ®Google Scholar
• Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76:513–17
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Perez MC, DeManno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endoc Rev 2005;26:423–38
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. VA2914 Study Group. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007;92:3582–9
   PubMed Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. UPA vs placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409–20
   PubMed Web of Science ®Google Scholar
• Donnez J, Tomaszewski J, Vazquez F, PEARL II Study Group, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421–32
   PubMed Web of Science ®Google Scholar
• Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol 2012;31:556–69
   PubMed Web of Science ®Google Scholar
• Donnez J, Vázquez F, Tomaszewski J, PEARL III and PEARL III Extension Study Group, et al. Long term treatment of uterine fibroids with UPA. Fertil Steril 2014;101:1565–73
   PubMed Web of Science ®Google Scholar
• Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of UPA in uterine fibroids. Fertil Steril 2015;103:519–27
   PubMed Web of Science ®Google Scholar
• Donnez J, Donnez O, Matule D, et al. Long term management of uterine fibroids with UPA. Fertil Steril 2016;105:165–73
   PubMed Web of Science ®Google Scholar
• Seitz C, Bumbuliene Ž, Costa AR, et al. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. Contemp Clin Trials 2017;55:56–62
   PubMed Web of Science ®Google Scholar
• Schultze-Mosgau MH, Schuett B, Hafner FT, et al. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women. Int J Clin Pharmacol Ther 2017;55:16–24
   PubMed Web of Science ®Google Scholar
• Schütt B, Kaiser A, Schultze-Mosgau MH, et al. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod 2016;31:1703–12
   PubMed Web of Science ®Google Scholar
• Heikinheimo O, Vani S, Carpén O, et al. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. Hum Reprod 2007;22:2515–22
   PubMed Web of Science ®Google Scholar
• Nayak NR, Slayden OD, Mah K, et al. Antiprogestin-releasing intrauterine devices: a novel approach to endometrial contraception. Contraception 2007;75(Suppl):S104–S11
   Web of Science ®Google Scholar
• Brache V, Sitruk-Ware R, Williams A, et al. Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women. Contraception 2012;85:480–8
   PubMed Web of Science ®Google Scholar
• Luyckx M, Squifflet JL, Jadoul P, et al. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril 2014;102:1404–9
   PubMed Web of Science ®Google Scholar